Efficacy of Chinese traditional quadruple single pill combination versus valsartan/hydrochlorothiazide for the treatment of hypertension (COSPQ-BP): study protocol for randomised controlled study
This study was registered at the Chinese Clinical Trials Registry (ChiCTR2300067920). The COSPQ-BP trial is currently enrolling. The study period will be from 1 January 2024 to 31 December 2025.
Authors
- Qingtao Meng (ORCID: https://orcid.org/0000-0002-1936-3050)
- Yan Yu (ORCID: https://orcid.org/0000-0002-4518-0573)
- Xiaoping Chen (ORCID: https://orcid.org/0009-0002-6652-4328)
- Xiangyu Yang (ORCID: https://orcid.org/0000-0003-1081-3657)
- Runyu Ye
- Lu Liu (ORCID: https://orcid.org/0000-0003-3289-8671)
- Kai Liu (ORCID: https://orcid.org/0000-0001-6039-2681)
- Si Wang (ORCID: https://orcid.org/0000-0002-4456-6706)
- Shanshan Jia (ORCID: https://orcid.org/0000-0002-3730-2702)
- Yuanyuan Yao (ORCID: https://orcid.org/0000-0002-7513-2919)
- Xianghao Zuo (ORCID: https://orcid.org/0009-0009-1594-5473)
- Xin Zhang (ORCID: https://orcid.org/0000-0003-0047-3134)
- Yanan Li (ORCID: https://orcid.org/0000-0002-4360-1987)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-092109
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sichuan University
- West China Hospital, Sichuan University